Latest News about BGNE
Recent news which mentions BGNE
Biogen's 2nd Alzheimer's Antibody, BeiGene's Cancer Drug Label Expansion, Adcom Test For Regeneron And More: January PDUFA Catalysts For Biotech Investors
December 27, 2022
From Benzinga
From Benzinga
BeiGene Earnings Perspective: Return On Capital Employed
December 12, 2022
Tickers
BGNE
From Benzinga
From Benzinga
Will Investors Notice Exciting Sign On BeiGene's Chart?
December 06, 2022
Tickers
BGNE
From Benzinga
Why Leslie's Shares Are Trading Lower By Over 9%? Here Are 60 Stocks Moving In Wednesday's Mid-Day Session
November 30, 2022
From Benzinga
Workday, XPeng, Titan Machinery And Some Other Big Stocks Moving Higher On Wednesday
November 30, 2022
From Benzinga
Why Horizon Therapeutics Shares Are Trading Higher By Over 30%; Here Are 32 Stocks Moving Premarket
November 30, 2022
From Benzinga
Quant Ratings Updated on 59 Stocks
November 29, 2022
From InvestorPlace
From Benzinga
Tesla, Amazon, Coupang, Rivian, Beigene: Musk's Share Sale, Antitrust Lawsuit, Earnings Grab Retail Investors' Eyeballs
November 09, 2022
From Benzinga
Is This Chinese Pharmaceutical Stock Worth the Risk?
November 03, 2022
Tickers
BGNE
From Motley Fool
Jazz Obtains Exclusive Rights To Zymeworks' Cancer Candidate In Almost $2B Biobuck Deal
October 19, 2022
From Benzinga
New Drugs Approvals Bring No Relief for Ailing Innovent Bio
October 18, 2022
From Benzinga
European Heath Agency's Committee Backs Approving BeiGene's Brukinsa In Leukemia Setting
October 14, 2022
Tickers
BGNE
From Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For October 13, 2022
October 13, 2022
From Benzinga
From Benzinga
UK's NICE Recommends BeiGene's Cancer Drug For Rare Form Of Blood Cancer
September 20, 2022
Tickers
BGNE
From Benzinga
BeiGene's Tislelizumab Shows Non-Inferiority In Overall Survival, Safety Vs Standard Treatment In Solid Tumors
September 12, 2022
From Benzinga
Junshi Biosciences Hits Revenue Roadblock Amid Covid Drug Delay
September 09, 2022
From Benzinga
U.S.-China Audit Deal Won't Slow Hong Kong Dual Listing Train, Analysts Say
September 02, 2022
From Benzinga
7 Chinese Stocks to Sell While You Still Can
September 02, 2022
From InvestorPlace
From Benzinga
Catalent, Tellurian And Other Big Losers From Monday
August 30, 2022
From Benzinga
U.S.-China relations just got a whole lot better, boosting the prospects of these three stocks
August 28, 2022
From MarketWatch
From Benzinga
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.